|
|
|
ARBEITSGRUPPE:
OKULÄRE
ENTZÜNDUNGEN und INFEKTIONEN
Leiterin: a.o. Univ. Prof.
Dr. Talin Barisani-Asenbauer
A d r e s s e:
Kinderspitalgasse 15, A-1090 Wien
Tel: +43-1-40 160-38260
Fax.: +43-1-40 160-938293
Email: talin.barisani@meduniwien.ac.at
|
|
|
LEBENSLAUF:
|
|
Von
|
bis
|
|
|
1971
|
1983
|
Lycee Francais de Vienne
|
|
1983
|
1990
|
Medizinstudium.
Dissertation: "Implementation of an Electronic Database in an Eye
Bank”
|
|
1987
|
1990
|
Wissenschaftliche MitarbeiterIn in der Hornhautbank
der 2 Univ. Augenklinik Wien
|
|
1990
|
1997
|
Facharztausbildung
|
|
1996
|
1997
|
Gegenfach Immunologie. Arbeitsgruppe Prof. Zlabinger
|
|
1997
|
|
Facharzt für Augenheilkunde und Optometrie
|
|
1998
|
|
Fellow
of the European Board of Ophthalmology
|
|
2001
|
|
Venia
docendi:” Molecular methods to identify microbes in ocular tissues“
|
|
POSITIONEN:
|
|
1990
|
1997
|
Universitätsassistentin der 2. Univ. Augenklinik Wien
|
|
1994
|
|
Leiterin der Uveitisambulanz der Klinik für
Augenheilkunde
|
|
1998
|
|
Oberärztin der Klinik für Augenheilkunde und
Optometrie
|
|
2002
|
|
Ao.univ.Prof. und Leiterin der Arbeitsgruppe
„Okuläre Immunologie“
|
|
2004
|
|
Österr.Delegierte:
European Board of Ophthalmology (EBO)
|
|
2004
|
|
Österr. Delegierte: Union Europeenne des Medecins
Specialistes (UEMS)
|
|
2007
|
2009
|
Vorsitzende der Kommission für Internationale
Ophthalmologie der ÖOG
|
|
2007
|
|
Generalsekretärin der International Ocular
Inflammation Society (IOIS)
|
|
2008
|
|
Arbeitsgruppe „Okuläre Entzündungen und
Infektionen“ am Institut für SPTM
|
|
2009
|
|
Vorsitzende der Kommission für Okuläre Immunologie,
Infektionen, Uveitis und Allergologie der ÖOG
|
|
2009
|
|
Präsidentin der Wiener Ophthalmologischen Gesellschaft
|
|
2010
|
|
Co-editor-in-chief
und Mitbegründerin: Journal of Ophthalmic Inflammation and Infection
|
|
MITARBEITERINNEN
Astrid Angel
Mag. Nora Bintner
Mag. Sandra Belij
Elvira Hilkevich
Dr. Aleksandra Inic-Kanada
Philipp Maier
Lamiss
Mejdoubi
Dr.
Jacqueline Montanaro-Punzengruber
Mag. Simone Schlacher
Mag.
Elisabeth Stein
FORSCHUNGSPROJEKTE:
• Okuläre Toxoplasmose
• Okuläre Toxokarose
• Okuläre Tuberkulose
• Chlamydieninfektionen und Uveitis
• Natürliche Immunantwort der Augenoberfläche- Veränderungen durch
Entzündungen und Infektionen
• Akanthamöben Keratitis
• Impfstoffentwicklung für die okuläre Chlamydia trachomatis Infektion
gemeinsam mit Bird-C (www.bird-c.at)
Ein innovatives, gendergerechtes Forschungsprogramm des Bundesministerium für
Wirtschaft, Familie und Jugend (BmWFJ) fördert die Errichtung eines Laura
Bassi Centres for Expertise: „Centre for ocular inflammation and
infection (OCUVAC)“ (
www.bmwfj.gv.at/BMWA/Presse/Aktuelle+Meldungen/20090707_01.htm)
“Knowledge for Global Sight Solutions”
The Centre for Ocular Inflammation and Infection –OCUVAC- is a
multidisciplinary, thematically integrated, cooperative research initiative
on the interface of fundamental research, practice and industrial
partnership. The aim of OCUVAC is to contribute to the global
community by developing strategies to prevent sight-threatening diseases. It
also has a strong education component with a focus on producing
scientists/graduates with skills relevant to industrial needs. Inter- and
transdisciplinary cooperative research is focused on identifying, undertaking
and supporting excellence in ocular vaccine development and related
technologies. The collaborative research will combine the scientific and
clinical expertise of the Medical University of Vienna with Bird-C expertise
in development of bacterial ghosts-based vaccines and proprietary
manufacturing process.
OCUVAC addresses issues related to women’s equality both through
research and services as well as within the organization. The primary
initiative will be the development of a trachoma vaccine against Chlamydia
trachomatis. Trachoma is the world’s leading cause of preventable
ocular disease and the third most common cause of blindness after cataract
and glaucoma, affecting an estimated 84 million people and leaving 590
million at risk. As a crippling disease, Trachoma causes an enormous loss of
productivity and constitutes a major socioeconomic burden. Children build up
a human reservoir for the spread of C.trachomatis and are the main cause for
reinfection in adults, predominantly the female caregivers, leaving women at
risk for blinding three times more than men.
Thus, an inexpensive and easy way to deliver vaccine for trachoma would be
highly effective in reducing the devastation caused by this disease.
An effective bacterial ghost (BG) delivery system possessing intrinsic
adjuvant properties and capable of simultaneously delivering multiple
antigens to the immune system has been developed by members of the
consortium. The safety and relatively cheap production cost of BG-based
vaccines offer a technological and manufacturing advantage for a vaccine
needed on a global scale.
OCUVAC aims at achieving a multidisciplinary understanding of trachoma and
ocular immunity that underpins the more translational research in the centre,
while having the potential for the discovery of innovative drug-delivery
systems and ocular vaccines.
Partner außerhalb der
Medizinischen Universität Wien
Prof. Dr. Werner Lubitz (Bird – C, Wien)
Prof. Dr. Andreas Schiesser (Sigmund Freud Universität, Wien)
Prof. Dr. Deborah Dean (Children Hospital Research Institute, San
Francisco USA)
Prof. Dr. Francis Eko (Morehouse School of Medicine, Atlanta USA)
Prof. Hristo Najdenski (Bulgarian Academy of Science, Sofia Bulgaria)
Pablo Goldschmidt (Hopital Quinze Vingt, Paris Frankreich)
Dr. S: P. Saikia (Mission Trust Bawri Nethralaya, Shillong Meghalaya, India)
Dr. Branislav R. Lazic (Torlak Institute of Virology, Vaccines and
Sera, Belgrad, Serbia)
|
